KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - Net
Ratios

Biomarin Pharmaceutical (BMRN) Other Gross PP&E Adjustments (2016 - 2025)

Biomarin Pharmaceutical (BMRN) has disclosed Other Gross PP&E Adjustments for 16 consecutive years, with $2.0 billion as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Other Gross PP&E Adjustments rose 6.62% year-over-year to $2.0 billion, compared with a TTM value of $2.0 billion through Dec 2025, up 6.62%, and an annual FY2025 reading of $2.0 billion, up 6.62% over the prior year.
  • Other Gross PP&E Adjustments was $2.0 billion for Q4 2025 at Biomarin Pharmaceutical, roughly flat from $2.0 billion in the prior quarter.
  • Across five years, Other Gross PP&E Adjustments topped out at $2.0 billion in Q3 2025 and bottomed at $1.7 billion in Q4 2021.
  • Average Other Gross PP&E Adjustments over 5 years is $1.9 billion, with a median of $1.9 billion recorded in 2023.
  • The sharpest move saw Other Gross PP&E Adjustments grew 9.73% in 2021, then dropped 0.94% in 2024.
  • Year by year, Other Gross PP&E Adjustments stood at $1.7 billion in 2021, then increased by 9.18% to $1.8 billion in 2022, then increased by 3.36% to $1.9 billion in 2023, then decreased by 0.94% to $1.9 billion in 2024, then rose by 6.62% to $2.0 billion in 2025.
  • Business Quant data shows Other Gross PP&E Adjustments for BMRN at $2.0 billion in Q4 2025, $2.0 billion in Q3 2025, and $2.0 billion in Q2 2025.